Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial

Cited by (675)

Items 401–500 of 675

1. Molecular Mechanism of Action of Repurposed Drugs and Traditional Chinese Medicine Used for the Treatment of Patients Infected With COVID-19: A Systematic Scoping Review
   F. Lem, Fernandes Opook, D. J. H. Lee · 2021 · Frontiers in Pharmacology
2. Clinical outcomes of COVID-19 in hemodialysis patients in the city of Zonguldak, Turkey
   Mahmud Islam, Y. Ozturk, Y. Koç · 2021 · International Urology and Nephrology
3. Review of pharmacologic and immunologic agents in the management of COVID-19
   Marzuq A. Ungogo, Mustapha Mohammed, Bala Ningi Umar, Auwal Adam Bala, Garba M. Khalid · 2021 · Biosafety and Health
4. An overview of potential therapeutic agents to treat COVID-19
   Xueqin Dong, Zhenxue Tian, Chengwu Shen, Cuirong Zhao · 2020 · BioScience Trends
5. A Randomized Controlled Study Of Favipiravir Vs Hydroxychloroquine In COVID-19 Management: What Have We Learned So Far?
   H. Dabbous, M. El-Sayed, Gihan El Assal et al. · 2020 · Research Square
6. FAVIPIRAVIR AS A POTENTIAL DRUG IN THE TREATMENT OF COVID-19
   D. G. Kramer, M. D. Da Silva, Gislanne Stéphanne Estevam da Silva · 2020 · International Journal of Research -GRANTHAALAYAH
7. Treatment Options for Severe Acute Respiratory Syndrome, Middle East Respiratory Syndrome, and Coronavirus Disease 2019: a Review of Clinical Evidence
   Tung Hoang, Tho Thi Anh Tran · 2020 · Infection and Chemotherapy
8. Statistical Issues and Lessons Learned From COVID-19 Clinical Trials With Lopinavir-Ritonavir and Remdesivir
   Yin, Guosheng, Zhang, Chenyang, Jin, Huaqing · 2020 · JMIR Public Health and Surveillance
9. Experimental evaluation of favipiravir (T-705)-induced liver and kidney toxicity in rats
   Menekşe Ülger, Işıl Tuğçe Turan, Ayşegül Si̇pahi̇, Gözde Özge Önder · 2025 · Food and Chemical Toxicology
10. Antiviral therapy for COVID-19 virus: A narrative review and bibliometric analysis
    Saeid Mezail Mawazi, Nousheen Fathima, Syed Mahmood, Sinan Mohammed Abdullah Al-Mahmood · 2024 · The American Journal of Emergency Medicine
11. Evaluation of the effect of favipiravir on patients with COVID-19
    Alireza Kamali, H. Sarmadian, Behnam Mahmoodiyeh · 2023 · Journal of Family Medicine and Primary Care
12. Early diagnosis by antigen test kit and early treatment by antiviral therapy: An ambulatory management strategy during COVID-19 crisis in Thailand
    N. Sayabovorn, P. Phisalprapa, W. Srivanichakorn et al. · 2022 · Medicine
13. Favipiravir and/or nitazoxanide: a randomized, double-blind, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE)
    Tania A. Smith, C. Hoyo‐Vadillo, Akosua Agyeman Adom et al. · 2022 · Trials
14. A trial of arbidol hydrochloride in adults with COVID-19
    Jing-Ya Zhao, Jinnong Zhang, Yang Jin et al. · 2022 · Chinese Medical Journal
15. Use of Favipiravir for the Treatment of Coronavirus Disease 2019 in the Setting of Hospitel
    Bhitta Surapat, Warissa Kobpetchyok, Sasisopin Kiertiburanakul, Vanlapa Arnuntasupakul · 2022 · International Journal of Clinical Practice
16. Favipiravir treatment does not influence disease progression among adult patients hospitalized with moderate-to-severe COVID-19: a prospective, sequential cohort study from Hungary
    B. Szabó, K. S. Lénárt, B. Petrik · 2021 · GeroScience
17. Pharmacological Effects of Favipiravir on Coronavirus: An Update
    P. Tejaswi, Kumar Devashish, R. Prasad · 2021 · Biomedical & Pharmacology Journal
18. Pharmacological Treatment for the Management of COVID-19: A Narrative Review
    Neelam Dhakal, Anil Poudyal, P. Gyanwali · 2021 · JNMA; journal of the Nepal Medical Association
19. Mutations in spike protein and allele variations in ACE2 impact targeted therapy strategies against SARS-CoV-2
    Chuanjun Shu, 南京医科大学公共卫生学院，江苏 南京211166，中国, Xuan Huang, Huihao Tang, Dingding Mo, Jianwei Zhou, Cheng Deng, 南京师范大学生命科学学院，江苏 南京 210023，中国, 南京医科大学生物医学工程与信息学院，江苏 南京 211166，中国, 南京大学医学院附属金陵医院生殖医学中心，江苏 南京 211166，中国 et al. · 2021 · 动物学研究
20. Experimental therapies under investigation for COVID-19
    R. Golamari, N. Kapoor, T. Devaraj · 2021 · Journal of Community Hospital Internal Medicine Perspectives
21. The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of COVID-19
    Farah Daou, Gretta Abou Sleymane, Danielle A. Badro, Nagham Léa Khanafer, Mansour A. Tobaiqy, Achraf Al Faraj · 2021 · International Journal of Environmental Research and Public Health
22. Single Dose, Two-way Crossover Bioequivalence Study of Favipiravir Tablet in Healthy Male Subjects
    O. Sağlam, G. Demiray, Berrak Güney · 2020
23. Basic Critical Care for Management of COVID-19 Patients: Position Paper of Indian Society of Critical Care Medicine, Part-I
    Manoj Singh, Suresh Ramasubban, Deven Juneja, Pavan Kumar Reddy, Palepu B. N. Gopal, Raymond Dominic Savio, Shubhal Dixit · 2020 · Indian Journal of Critical Care Medicine
24. Coronavirus Disease 2019: A Brief Review of the Clinical Manifestations and Pathogenesis to the Novel Management Approaches and Treatments
    Omid Kooshkaki, Afshin Derakhshani, Andelé M. Conradie, Nima Hemmat, Savio George Barreto, Amir Baghbanzadeh, Pankaj K. Singh, Hossein Safarpour, Zahra Asadzadeh, Souzan Najafi et al. · 2020 · Frontiers in Oncology
25. A Summary of Coronavirus Disease 2019: What We Should Know?
    Ysrafil Ysrafil, Indwiani Astuti, Rosdiana Mus, Noviyanty Indjar Gama, Dwi Rahmaisyah, Riskah Nur’amalia · 2020 · Pharmaceutical Sciences
26. Medical management of COVID-19 clinic
    N. Mehta, R. Qiao · 2020 · Journal of Biomedical Research
27. What Is the Best Drug to Treat COVID-19? The Need for Randomized Controlled Trials
    S. Ottaviani, J. Stebbing · 2020 · i Medicina
28. Exploring pathophysiology of COVID-19 infection: Faux espoir and dormant therapeutic options
    Vinod Nikhra · 2020 · International Journal of Clinical Virology
29. Convenient screening of the reproductive toxicity of favipiravir and antiviral drugs in Caenorhabditis elegans
    Kimiyasu Shiraki, Mizuki Mishima, Noriaki Sato, Yasuo Imoto, Kiyoji Nishiwaki · 2024 · Heliyon
30. OPTIMIZING DRUG DISCOVERY: AN OPPORTUNITY AND APPLICATION WITH REVERSE TRANSLATIONAL RESEARCH
    P. Musyuni, Ruchika Sharma, G. Aggarwal · 2022 · Health Sciences Review
31. How pragmatic are randomized trials of remdesivir and favipiravir for in-hospital treatment of COVID-19: a descriptive methodological review of trial design using the PRECIS-2 framework
    Tanmay Sharma, Intisar Qamar, M. Zwarenstein · 2022 · Journal of Clinical Epidemiology
32. Expediting the drug discovery for ideal leads against SARS-CoV-2 via molecular docking of repurposed drugs
    Akanksha Sharma, Mandeep Kaur, Priya Yadav, Gurpal Singh, Ravi Pratap Barnwal · 2022 · Journal of Biomolecular Structure and Dynamics
33. Evaluation of the Safety and Efficacy of Favipiravir in Adult Indian Patients with Mild-to-Moderate COVID-19 in a Real-World Setting
    P. Reddy, Saiprasad Patil, Akash Khobragade et al. · 2022 · International Journal of General Medicine
34. De Novo In-silico Pharmacological Analysis of Herbal Phytoconstituents for COVID-19 Treatment
    Safiya Sultana T, U. S., S. M. · 2022 · Research Journal of Pharmacy and Technology
35. Interplay of Nutrition and Psychoneuroendocrineimmune Modulation: Relevance for COVID-19 in BRICS Nations
    Arundhati Mehta, Yashwant Kumar Ratre, Krishna Sharma, Vivek Kumar Soni, Atul Kumar Tiwari, Rajat Pratap Singh, Mrigendra Kumar Dwivedi, Vikas Chandra, Santosh Kumar Prajapati, Dhananjay Shukla et al. · 2021 · Frontiers in Microbiology
36. A Systematic Review on COVID 19 Treatment and Management
    Isha Shah, Nensi Raytthatha, Jigar Vyas, Umesh Upadhyay · 2021 · Research Journal of Pharmaceutical Dosage Forms and Technology
37. Assessment of clinical outcomes in renal transplant recipients with COVID‐19
    G. Yilmaz, Ozdemir Ebru, Berber Ibrahim · 2021 · Journal of Medical Virology
38. Hydroxychloroquine/chloroquine in patients with COVID-19 in Wuhan, China: a retrospective cohort study
    Zhe Chen, Aihua Liu, Yongjing Cheng, Xutao Wang, Xiaomao Xu, Jia Huang, Yuqing Ma, Ming Li Gao, Cibo Huang · 2021 · BMC Infectious Diseases
39. The Efficacy and Adverse Effects of Favipiravir on COVID-19 Patients: A Systematic Review and Meta-Analysis of Published Clinical Trials and Observational Studies
    Dang The Hung, Suhaib Ghula, Jeza Muhamad Abdul Aziz, Abdelrahman M Makram, Gehad Mohamed Tawfik, Ali Ahmed‐Fouad Abozaid, Rohan Andrew Pancharatnam, Amr Mohamed Ibrahim, Muhammad Besher Shabouk, Morgan Turnage et al. · 2021 · SSRN Electronic Journal
40. Repositioned Drugs for COVID-19—the Impact on Multiple Organs
    Christina Chan, Sean T. Foster, Kayla G. Chan, Matthew J. Cacace, Shay Ladd, Caleb T. Sandum, Paul T. Wright, Brett D. Volmert, Weiyang Yang, Aitor Aguirre et al. · 2021 · SN Comprehensive Clinical Medicine
41. An Updated Systematic Review and Network Meta-Analysis of 25 Randomized Trials Assessing the Efficacy and Safety of Treatments in Covid-19 Disease
    Alhassane Diallo, Miguel Carlos‐Bolumbu, Traoré Marie, Mamadou Diallo, Christophe Jedrecy · 2021 · Journal of Public Health Research
42. Results of Favipiravir Combined Treatment in Intensive Care Patients With Covid-19
    Habip Yılmaz, A. Güner, M. Altuntaş · 2020 · Bagcilar Medical Bulletin
43. Detailed disease progression of 213 patients hospitalized with Covid-19 in the Czech Republic: An exploratory analysis
    Martin Modrák, Paul-Christian Bürkner, T. Sieger et al. · 2020 · medRxiv
44. DFT and TD-DFT Study of Favipiravir Tautomerism as RNA Polymerase Inhibitors : COVID-19
    Hammood M. Yasir, Falah H. Hanoon · 2020 · IOP Conference Series: Materials Science and Engineering
45. COVID-19 Treatment at a Glance
    Hüseyin Arıkan, Dilek Karadoğan, Fatma Tokgöz Akyıl, Aycan Yüksel, Zehra Nur Töreyin, Canan Gunduz Gurkan, Feride Marım, Tuğba Şişmanlar Eyüboğlu, Nagehan Emiralioğlu, Tuğba Ramaslı Gürsoy et al. · 2020 · Turkish Thoracic Journal
46. Traveling for heart transplantation and returning with COVID-19: a logistical, clinical, and pharmacotherapeutic challenge from the Middle East
    Bassam Atallah, Iman Mukhtar Hamour, Saad I. Mallah, Maria-Fernanda Bonilla, Feras M. Bader · 2020 · Drugs & Therapy Perspectives
47. Screening of potential inhibitors of COVID-19 with repurposing approach via molecular docking
    Negin Alizadehmohajer, Abtin Behmardi, Simin Najafgholian, Shabnam Moradi, Forogh Mohammadi, Reza Nedaeinia, Shaghayegh Haghjooy Javanmard, Ehsan Sohrabi, Rasoul Salehi, Gordon A. Ferns et al. · 2022 · Network Modeling Analysis in Health Informatics and Bioinformatics
48. Study Design Characteristics and Pharmacological Mechanisms in International Clinical Trials Registry Platform: Registered Clinical Trials on Antiviral Drugs for COVID-19
    Weilong Zhang, Ying-Hua Lv, Juan Yang · 2020 · Drug Design, Development and Therapy
49. COVID19 inhibitors: A prospective therapeutics
    Md Jawaid Akhtar · 2020 · Bioorganic Chemistry
50. Anti-cytokine therapy in novel coronavirus disease (COVID-19) – the first administration of tocilizumab in Hungary at a department of infectology
    Botond Lakatos, László Gopcsa, Enikő Gondos, Alexandra Riczu, Zsuzsa Várnai, Eva Livia Nagy, Eszter Molnár, Gabriella Bekő, Ilona Bobek, Peter Pal Remenyi et al. · 2020 · PubMed
51. Virtual Screening of Plant Metabolites against Main protease, RNA-dependent RNA polymerase and Spike protein of SARS-CoV-2: Therapeutics option of COVID-19
    Parvez, Md Sorwer Alam, Kazi Faizul Azim, Imran As, Topu Raihan, Begum, Aklima, Tasfia Saiyara Shammi, Sabbir Howlader, Farhana Rumzum Bhuiyan, Mahmudul Hasan · 2020 · arXiv (Cornell University)
52. Chinese Clinical Studies for Pharmacological Treatments of Coronavirus Disease 2019 (COVID-19)
    Ru Han, Yi-Tong Wang, M. Dabbous · 2020
53. Critical Review and Analysis of Approval of Favipiravir for Restricted Emergency Use in Mild-to-Moderate COVID-19
    Arunkumar Radhakrishnan, R. Arunachalam, A. Elango · 2020 · Journal of Pharmacology and Pharmacotherapeutics
54. A review on the mechanism of action of favipiravir and hydroxychloroquine in COVID-19
    V. Pavlova, S. Hristova, K. Uzunova · 2021 · Research and Review Insights
55. Clinical Synopsis of COVID-19: Evolving and Challenging
    H. Prabhakar · 2020
56. The Real-World Clinical Outcomes of Favipiravir Treatment with Telemedicine Monitoring in Preventing Disease Progression in Mild to Moderate COVID-19 Patients; A Retrospective Cohort Study
    T. Siripongboonsitti, K. Tawinprai, Kunsuda Cheirsilpa · 2023 · Medicina
57. Real-World Experience with Favipiravir for the Treatment of Mild-to-Moderate COVID-19 in India
    Shashank R. Joshi, A. Vora, K. Venugopal · 2022 · Pragmatic and Observational Research
58. Antiviral Used among Non-Severe COVID-19 Cases in Relation to Time till Viral Clearance: A Retrospective Cohort Study
    Wael Hafez, H. Saleh, Ziad Al Baha · 2022 · Antibiotics
59. Current Potential Options for COVID-19 Treatment in Iraq- Kurdistan Region and the Rest of the World: A Mini-review
    Aryan Mahmood Faraj, Syamand Ahmed Qadir, Othman Abdulrahman Mohammed, Peshawa Yunis Aziz, Marwa Alkhafaji, Heshu Sulaiman Rahman, Jeza Muhamad Abdul Aziz, Hemn Hassan Othman, Adel Mohan Adai AL-Zubaidy · 2022 · Iraqi Journal of Science
60. Pharmacoeconomic Analysis of Treatment Regimens for Coronavirus Infection Coronavirus Disease-19
    O. Krylova, A. Krasheninnikov, E. Mamontova · 2021 · Open Access Macedonian Journal of Medical Sciences
61. Phase II Clinical Trial of Combination Therapy with Favipiravir and Methylprednisolone for COVID-19 with Non-Critical Respiratory Failure
    Y. Shindo, Y. Kondoh, A. Kada et al. · 2021 · Infectious Disease and Therapy
62. COVID-19 with Rapid Progression to Hypoxemia Likely due to Imbalance between Ventilation and Blood Flow: A Case Report
    N. Koriyama, Akihiro Moriuchi, K. Higashi · 2021 · Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine
63. An Overview of COVID-19 Treatment: Possible Candidates Based on Drug Repurposing and Molecular Docking
    Mai Abdelgawad, Sahar A. Allam, Maha Abdelmonaem Shaheen, Mohamed Ali Hussein, Hoda Azmy Elkot, Aya A. Gaber, Khaled A. Marghany, Asmaa A. Abdelwahab, Rewan H. Alashrey, Hoda Y. Abdallah · 2021 · Canadian Journal of Medicine
64. Target SARS-CoV-2: theoretical exploration on clinical suitability of certain drugs
    S. M. Abdul Nayeem, Ershad Mohammed Sohail, N. V. Srihari, P. Indira, Munnangi Srinivasa Reddy · 2021 · Journal of Biomolecular Structure and Dynamics
65. A Narrative Review of Antiviral Drugs Used for COVID-19 Pharmacotherapy
    Subodh Kumar, M. Saurabh, V. Maharshi · 2021 · Journal of Pharmacy and Bioallied Sciences
66. Emerging therapeutics in the management of COVID-19
    Asim Kichloo, Michael Stanley Albosta, Akshay Kumar, Michael M. Aljadah, Mohamed Mohamed, Zain El‐amir, Farah Wani, Shakeel Muhammad Jamal, Jagmeet Singh, Akif Ahmed Kichloo · 2021 · World Journal of Virology
67. Safety of pharmacological options for the management of COVID-19 in pregnant women: An Indian perspective
    Kavita Manchanda, Jasbir Singh, Ranjeev Bhagat, Ilmjot Kaur Tiwana, Harmanjit Singh · 2020 · International Journal of Risk & Safety in Medicine
68. Current and future use of favipiravir in patients with COVID-19
    A. V. Matveev, Yury Kiselev, D. Sychev · 2020 · Kachestvennaya klinicheskaya praktika
69. Drug Design and Repurposing with DockThor-VS Web Server: Virtual Screening focusing on SARS-CoV-2 Therapeutic Targets and their Non-Synonym Variants
    I. Guedes, Leon S. C. Costa, K. D. Dos Santos et al. · 2020
70. Recent Updates in the Pharmacological Management of COVID-19
    N. Maideen · 2020 · Letters in Applied NanoBioScience
71. COVID-19 FARMAKOTERAPİSİ
    Begüm Yurdakök-Di̇kmen, Yağız Pat, Ergin Dileköz, Gökçe Yağmur Summak, Oğuz Kul, Ayhan Filazı · 2020 · Veteriner Farmakoloji ve Toksikoloji Derneği Bülteni
72. PHARMACOLOGICAL TREATMENTS OF COVID-19 – A REVIEW
    Jeeja Mathummal Cherumanalil, Jayakrishnan Thayyil · 2020 · Asian Journal of Pharmaceutical and Clinical Research
73. Treatment Armamentarium of COVID-19: Evolving Strategies and Evidence So Far
    Swapnil Dhampalwar, Sanjiv Saigal, Arvinder Singh Soin · 2020 · Journal of Clinical and Experimental Hepatology
74. Revealing Potential Binding Affinity of FDA Approved Therapeutics Targeting Main Protease (3CLpro) in Impairing Novel Coronavirus (SARSCoV- 2) Replication that Causes COVID-19
    Dhanasekaran Sivaraman, P. S. Pradeep, Solomon Sundar Manoharan, Chandra R. Bhat, KagithakaraVajravelu Leela, V. Venugopal · 2020 · Coronaviruses
75. Adjunctive favipiravir for severe COVID-19: a retrospective observational study of the first 41 patients in Thailand
    Wisit Prasithsirikul, Krit Pongpirul, Phuwanat Sakornsakolpat · 2020 · Asian Biomedicine
76. A comprehensive review of COVID-19 treatment
    Zeinab Mohseni Afshar, Arefeh Babazadeh, Mostafa Javanian, Mohammad Barary, Vasigala Rekha, Soheil Ebrahimpour · 2020 · AFMN Biomedicine
77. Clinical effectiveness, safety, and viral mutagenicity of oral favipiravir for COVID-19: results from a community-based, open-label, randomized Phase III trial
    Matthew Tate, Christopher J. R. Illingworth, Gordon MacGregor et al. · 2025 · Antimicrobial Agents and Chemotherapy
78. A randomized trial to assess the acceleration of viral clearance by the combination Favipiravir/Ivermectin/Niclosamide in mild-to-moderate COVID-19 adult patients (FINCOV)
    Taweegrit Siripongboonsitti, Kriangkrai Tawinprai, Panisadee Avirutnan, Kunlakanya Jitobaom, Prasert Auewarakul · 2024 · Journal of Infection and Public Health
79. Molecular dynamic simulation reveals spider antimicrobial peptide Latarcin-1 and human eosinophil cationic protein as peptide inhibitors of SARS-CoV-2 variants
    Cheng Cao, Aamir Mehmood, Daixi Li · 2023 · Journal of Biomolecular Structure and Dynamics
80. Favipiravir for the treatment of COVID-19 in elderly patients—what do we know after 2 years of COVID-19?
    H. Papp, Z. Lanszki, G. Keserű · 2022 · GeroScience
81. Clinical progress of therapeutics and vaccines: Rising hope against COVID-19 treatment
    Ravi Bandaru, Smruti Rekha Rout, Omkar Kamble, Sangram Keshari Samal, Bapi Gorain, Amirhossein Sahebkar, Farhan Ahmed, Prashant Kesharwani, Rambabu Dandela · 2022 · Process Biochemistry
82. Favipiravir for the treatment of COVID-19 pneumonia: Can we predict the response to treatment?
    A. Sayıner, H. Erdem, Pervin Korkmaz Ekren · 2022 · Journal of Infection in Developing Countries
83. Discovery of compounds inhibiting SARS-COV-2 multi-targets
    Santanu Sasidharan, Neellohit Sarkar, Prakash Saudagar · 2022 · Journal of Biomolecular Structure and Dynamics
84. Characteristics of the COVID-19 patients treated at Gulu Regional Referral Hospital, Northern Uganda: A cross-sectional study
    Steven Baguma, Christopher Okot, Nelson Alema Onira et al. · 2021
85. Theory and reality of antivirals against SARS-CoV-2
    Bo Zhao, Tengfei Yang, Rui Zheng · 2021 · World Journal of Clinical Cases
86. Coronavirus Disease 2019 (COVID-19): Origin, Impact, and Drug Development
    Amaresh Mishra, Nisha Nair, Amit K. Yadav, Pratima Rathee Solanki, Jaseela Majeed, Vishwas Tripathi · 2021 · IntechOpen eBooks
87. Pharmacotherapy for COVID-19: A Ray of Hope
    Mayank Kapoor, Prasan Kumar Panda, Vivek Mohanty · 2021 · IntechOpen eBooks
88. Pharmacotherapy of COVID-19: Considerations for Pregnancy and Breastfeeding
    A. Naseri, Sepideh Seyedi Sahebari, Mohammad-Salar Hosseini · 2021 · Journal of Obstetrics Gynecology and Cancer Research
89. Inhibition mechanism and hot-spot prediction of nine potential drugs for SARS-CoV-2 M pro by large-scale molecular dynamic simulations combined with accurate binding free energy calculations
    Song Luo, Kaifang Huang, Xiaoyu Zhao, Yalong Cong, John Z. H. Zhang, Lili Duan · 2021 · Nanoscale
90. Investigation of the disease process and drug combinations in patients with suspected/confirmed COVID‐19 using favipiravir
    M. Oruç, H. Öz, Onur Öztürk · 2021 · International journal of clinical practice
91. High-risk exposure without personal protective equipment and infection with SARS-CoV-2 in-hospital workers - The CoV-CONTACT cohort
    Sarah Tubiana, Charles Burdet, Nadhira Houhou‐Fidouh, Michaël Thy, Pauline Manchon, François Blanquart, Charlotte Charpentier, Jérémie Guedj, Loubna Alavoine, Sylvie Behillil et al. · 2021 · Journal of Infection
92. A Systematic Review and Network Meta-Analysis for COVID-19 Treatments
    Chenyang Zhang, Huaqing Jin, Yifeng Wen, Guosheng Yin · 2020 · medRxiv
93. Role of favipiravir in the treatment of adult patients with moderate to severe COVID-19: a single-center, prospective, observational, sequential cohort study from Hungary
    B. Szabó, K. S. Lénárt, B. Petrik et al. · 2020 · medRxiv
94. Review the Use of Antivirus for COVID-19 Treatment
    Lukman Prayitno, Julien Rosye Mawuntu, Herna, Tri Juni Angkasawati · 2020 · Journal of Health Management
95. Structural basis for the inhibition of the SARS-CoV-2 RNA-dependent RNA polymerase by favipiravir-RTP
    K. Naydenova, K. Muir, Long-Fei Wu et al. · 2020 · bioRxiv
96. Potential Drugs for Treating COVID-19 Infection
    Mehrdad Mohammadi, Tim Sandle, Sajad Rajabi, Ahmad Khorshidi, Ahmad Piroozmand · 2020 · International Journal of Infection
97. Review of COVID-19 Treatment
    S. Sadeghi, M. Momenzadeh, Peiman Nasri · 2020 · Journal of Research in Pharmacy Practice
98. Facts and Recommendations of SARS-CoV-2 and COVID-19: An Update
    The BASE Medicine Task Force · 2020 · Science Insights
99. Novel immunogenomic insights of corona virus disease (COVID-19): Available potential immunotherapeutics, current challenges, immune cell recognition and ongoing managerial strategies
    Kabeer Haneef, Muhammad Umer Asghar, Ashiq Ali · 2020 · Biomedical Research and Therapy
100. Pride and Prejudice during the COVID-19 Pandemic: The Misfortune of Inappropriate Clinical Trial Design
     S. Hashmi, E. D. De Vol, F. Hussain · 2020 · Journal of Epidemiology and Global Health